Search results for "lino"

showing 10 items of 1310 documents

Globorotalia truncatulinoides in the Mediterranean Basin during the Middle–Late Holocene: Bio-Chronological and Oceanographic Indicator

2022

The planktonic foraminiferal species Globorotalia truncatulinoides is widely used as a biostratigraphic proxy for the Quaternary in the Mediterranean region. High-resolution quantitative studies performed on sediment cores collected in the central and western Mediterranean Sea evidence a significant abundance of G. truncatulinoides during the Middle Holocene. The robust chronological frame allows us to date this bio-event to 4.8–4.4 ka Before Present (BP), very close to the base of the Meghalayan stage (4.2 ka BP). As a consequence, we propose that G. truncatulinoides can be considered a potential marker for the Middle–Late Holocene chronological subdivision. G. truncatulinoides is a deep-d…

<i>Globorotalia truncatulinoides</i>; Meghalayan stage; 4.2 event; vertical mixing; Mediterranean SeaGloborotalia truncatulinoides4.2 eventGloborotalia truncatulinoides; Meghalayan stage; 4.2 event; vertical mixing; Mediterranean Seavertical mixingMediterranean SeaGeneral Earth and Planetary SciencesMeghalayan stageSettore GEO/01 - Paleontologia E Paleoecologia
researchProduct

Quantitative analysis of the effect of controlled-release formulation on nonlinear gastrointestinal absorption of P-glycoprotein substrate talinolol …

2020

Abstract Oral absorption of talinolol, a substrate of P-glycoprotein (P-gp), from a sustained-release (SR) formulation was reportedly decreased compared to that from an immediate-release (IR) formulation. The aim of this study was to predict and understand the effect of controlled-release formulation on the oral absorption of P-gp substrates by developing a physiologically based pharmacokinetic (PBPK) absorption model incorporating multiple kinetic parameters obtained from in vitro studies, using talinolol as a model substrate. Simulation analysis using the developed PBPK absorption model indicated that the clinically observed marked decrease in the plasma concentration of talinolol adminis…

Absorption (pharmacology)Physiologically based pharmacokinetic modellingChromatographyPharmaceutical ScienceSubstrate (chemistry)02 engineering and technology021001 nanoscience & nanotechnology030226 pharmacology & pharmacyControlled releaseIntestinal absorption03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistryPharmacokinetics0210 nano-technologyQuantitative analysis (chemistry)TalinololJournal of Drug Delivery Science and Technology
researchProduct

Physiologische Wirkungen und Stoffwechsel dimerer Fettsäuren

1964

Die langfristige Verfutterung von 5% dimeren Fettsauren entspr. rund 1,5 g/kg Korpergewicht (bezogen auf das Endgewicht) ergab toxische Wirkungen: Wachstumsverzogerungen, verschlechterte Futterefficiency, Verschlechterung des Grundumsatzes, Senkung der Korpertemperatur, Storung der Leberfunktion und Ablagerung eines abnormen Pigments im RES und in Organzellen.

Absorption (pharmacology)chemistry.chemical_compoundChromatographychemistryLinoleic acidMedicine (miscellaneous)Pyruvic acidMetabolismBiochemistryFood ScienceZeitschrift für Ernährungswissenschaft
researchProduct

Synthesis of novel organic-based fluorophores – Implementation to the design of fluorogenic enzyme substrates based on the principle of in situ synth…

2020

Detection and fluorescence imaging of biologic systems requires the implementation of efficient, robust and easy-to-use tools. Conventional fluorogenic probes currently used in microbiology lack efficiency since they are based on the single chemical modification of a fluorophore bearing an optically tunable reactive group, which often leads to incomplete fluorescence quenching. The main goal of my Ph.D thesis was to develop novel fluorogenic enzymatic substrates based on the "covalent assembly" principle. This approach also named "in situ synthesis" is based on the use of domino reactions to form a fluorescent moiety starting from a "caged" non-fluorescent molecule. In our case, the bioanal…

Activation enzymatique[CHIM.ORGA]Chemical Sciences/Organic chemistryHétéro-XanthènesSynthèse in situHetero-Xanthene dyesQuinoxalinonesIn situ synthesis[CHIM.ORGA] Chemical Sciences/Organic chemistryEnzymatic activationFluorogenic probesSonde fluorogéniquesFluorescence
researchProduct

Value of Quantitative DNA Analysis in Endocrine Tumors of the Pancreas

1997

The diagnosis of malignancy can be difficult in endocrine tumors of the pancreas. Moreover prognostically relevant factors are not available. The aim of this study was to evaluate retrospectively whether the DNA distribution pattern can differentiate between benign and malignant pancreatic endocrine tumors and secondly whether the DNA content of tumor cells gives prognostic information.Image cytometry of paraffin-embedded tumor material of 42 pancreatic endocrine tumors.In 27 benign endocrine pancreatic tumors (25 insulinomas, 2 benign nonfunctioning endocrine tumors) we could differentiate between 6 diploid, 15 hypotriploid and 6 triploid DNA histograms. In 15 malignant endocrine tumors of…

AdenomaAdultMaleCancer ResearchPathologymedicine.medical_specialtyPancreatic diseaseAdolescentBiologyMalignancychemistry.chemical_compoundmedicineHumansEndocrine systemEndocrine pancreatic tumorsAgedRetrospective StudiesPloidiesfungifood and beveragesDNA NeoplasmGeneral MedicineMiddle AgedAdenoma Islet CellPrognosismedicine.diseasePancreatic Neoplasmsmedicine.anatomical_structureOncologychemistryFemaleInsulinomaPancreasDNAOncology
researchProduct

Dietary fatty acids and recurrence of colorectal adenomas in a European intervention trial.

2008

Epidemiological studies have provided inconsistent data about the role of dietary fatty acids in colorectal cancer, and few studies have addressed their role in colorectal adenoma. The aim of the study was to assess the risk of overall adenoma recurrence associated with dietary consumption of total fat, subtypes of fat, and specific fatty acids (oleic acid, linoleic acid, alpha-linolenic acid). The study sample was composed of 523 patients with confirmed adenomas at the index colonoscopy, 35 to 75 yr old, who completed the European fiber-calcium intervention trial and had an initial dietary assessment using a qualitative and quantitative food questionnaire. The overall 3-yr recurrence rate …

AdenomaAdultMaleCancer Researchmedicine.medical_specialtyAdenomaColorectal cancerLinoleic acidMedicine (miscellaneous)Colorectal adenomaGastroenterologyLinoleic Acidchemistry.chemical_compoundRisk FactorsInternal medicineSurveys and QuestionnairesEpidemiologymedicineOdds RatioHumansAgedchemistry.chemical_classificationNutrition and Dieteticsbusiness.industryFatty AcidsOdds ratioMiddle Agedmedicine.diseaseDietary FatsDietEuropeOleic acidOncologychemistryFatty Acids UnsaturatedFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsPolyunsaturated fatty acidNutrition and cancer
researchProduct

MEN1 Disease Occurring Before 21 Years Old: A 160-Patient Cohort Study From the Groupe d'étude des Tumeurs Endocrines

2015

Multiple endocrine neoplasia Type-1 (MEN1) in young patients is only described by case reports.To improve the knowledge of MEN1 natural history before 21 years old.Obtain a description of the first symptoms occurring before 21 years old (clinical symptoms, biological or imaging abnormalities), surgical outcomes related to MEN1 Neuro Endocrine Tumors (NETs) occurring in a group of 160 patients extracted from the "Groupe d'étude des Tumeurs Endocrines" MEN1 cohort.The first symptoms were related to hyperparathyroidism in 122 cases (75%), pituitary adenoma in 55 cases (34%), nonsecreting pancreatic tumor (NSPT) in 14 cases (9%), insulinoma in 20 cases (12%), gastrinoma in three cases (2%), mal…

AdenomaAdultMalemedicine.medical_specialtyAdolescentendocrine system diseasesAdenomaEndocrinology Diabetes and MetabolismClinical BiochemistryAdrenal Gland NeoplasmsContext (language use)BiochemistryCohort StudiesYoung AdultEndocrinologyPancreatic tumorPituitary adenomaInternal medicineMultiple Endocrine Neoplasia Type 1medicineHumansPituitary NeoplasmsAge of OnsetChildMultiple endocrine neoplasiaGastrinomabusiness.industryBiochemistry (medical)Infantmedicine.diseasePancreatic NeoplasmsNeuroendocrine TumorsEndocrinologyChild PreschoolFemaleInsulinomaFranceAge of onsetbusinessCohort studyThe Journal of Clinical Endocrinology &amp; Metabolism
researchProduct

‘La chiamiamo con entrambi i nomi’: eponimia ed eteronimia tra Nemesis e Adrasteia

2020

Prendendo le mosse da un passo di Ammiano Marcellino (XIV 11,25), che lascia emergere un’evidente sovrapposizione tra la figura di Adrasteia e quella Nemesis, il contributo si propone di esaminare le ragioni che hanno condotto le due potenze ad essere indicate l’una come l’eteronimo dell’altra. A partire dalle fonti di V secolo fino alla paremiografia e alla lessicografia di età imperiale si ricostruisce un percorso che si propone di mostrare gli accidenti e le molteplici variabili cui le logiche di denominazione del divino, nel mondo greco, possono essere soggette. Starting from a passage by Ammiano Marcellino (XIV 11,25), which reveals an evident overlap between the figure of Adrasteia an…

AdrasteiaHistoryAdrastosNemesisCroesusHerodotusErodotoLexicographySettore L-ANT/02 - Storia GrecaAmmiano Marcellino Adrasteia Nemesis Herodotus Croesus Adrastos Greek ancient ReligionAdrastoAmmiano Marcellino Adrasteia Nemesis Erodoto Creso Adrasto Religione greca anticaPath (graph theory)General Earth and Planetary SciencesCresoHumanitiesGeneral Environmental Science
researchProduct

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Canc…

2018

AbstractPurpose: This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer.Patients and Methods: Patients received 6-mg oral taselisib capsules daily plus intramuscular fulvestrant (500 mg) until disease progression or unacceptable toxicity. Tumor tissue (if available) was centrally evaluated for PIK3CA mutations. Adverse events (AE) were recorded using NCI-CTCAE v4.0. Tumor response was investigator-determined using RECIST v1.1.Results: Median treatment duration was 4.6 (range: 0.9–40.5) months. All patients expe…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Phases of clinical researchBreast NeoplasmsDisease-Free SurvivalArticle03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectFulvestrantAgedAged 80 and overResponse rate (survey)Fulvestrantbusiness.industryImidazolesCancerMiddle Agedmedicine.diseaseOxazepines030104 developmental biologyReceptors EstrogenOncologyHormone receptor030220 oncology & carcinogenesisMutationToxicityFemalebusinessmedicine.drugClinical Cancer Research
researchProduct

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

2016

// Daniela Massihnia 1,* , Antonio Galvano 1,* , Daniele Fanale 1 , Alessandro Perez 1 , Marta Castiglia 1 , Lorena Incorvaia 1 , Angela Listi 1 , Sergio Rizzo 1 , Giuseppe Cicero 1 , Viviana Bazan 1 , Sergio Castorina 2,3,** and Antonio Russo 1,** 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 3 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy * These authors have contributed equally to this work ** Both the authors are last name Correspondence to: Antonio Russo, email: // Keywords : ER, HER2, PI3K/AKT/mTOR inhib…

Adult0301 basic medicineOncologymedicine.medical_specialtyPathologyAntineoplastic AgentsTriple Negative Breast NeoplasmsReviewTarget therapyPhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineBreast cancerHER2Internal medicineDrug DiscoverymedicineCarcinomaHumansTriple negative breast cancerTarget therapyER; HER2; PI3K/AKT/mTOR inhibitor; Target therapy; Triple negative breast cancer; OncologySurvival rateProtein kinase BPI3K/AKT/mTOR pathwayTriple-negative breast cancerAgedClinical Trials as Topicbusiness.industryTOR Serine-Threonine KinasesAge FactorsMiddle Agedmedicine.diseaseOncogene Protein v-aktClinical trial030104 developmental biologyEROncology030220 oncology & carcinogenesisFemalePI3K/AKT/mTOR inhibitorbusinessSignal TransductionOncotarget
researchProduct